Abstract
DeVries (1) was surprised that vildagliptin and sitagliptin groups reported different mean amplitude of glycemic excursions (MAGE) reduction because they have similar fasting and postprandial glucose levels and suggested reporting other measures of glucose variability to better understand these results. Indeed, a previous study evaluating the role of glycemic variability in type 2 diabetic patients has demonstrated that patients with similar mean glucose and postprandial glucose have a markedly different daily glucose profile with differences both in number and duration of excursions (2). The difference in MAGE reduction found in the two study groups …
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have